{"name":"Amylyx Pharmaceuticals Inc.","slug":"amylyx-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"Amylyx Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for neurodegenerative diseases. The company's lead candidate, AMX0035, is in Phase 3 trials for amyotrophic lateral sclerosis (ALS).","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":380786000,"revenueGrowth":1612.9,"grossMargin":0,"rdSpend":90404000,"netIncome":-144735000,"cash":226651000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AMX0114","genericName":"AMX0114","slug":"amx0114","indication":"Other","status":"phase_1"},{"name":"AMX0035","genericName":"AMX0035","slug":"amx0035","indication":"Amyotrophic lateral sclerosis (ALS)","status":"phase_3"}]}],"pipeline":[{"name":"AMX0114","genericName":"AMX0114","slug":"amx0114","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMX0035","genericName":"AMX0035","slug":"amx0035","phase":"phase_3","mechanism":"AMX0035 is a fixed-dose combination of sodium phenylbutyrate and taurursodiol that reduces neuroinflammation and protects motor neurons by stabilizing mitochondrial function and reducing ER stress.","indications":["Amyotrophic lateral sclerosis (ALS)"],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-03-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-03","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQTTU1czh4S0h0SkdNTHhicTJvcllRemRNYmQtZnVLX0l4Yl9VUVFvN1ZjU0JxSFF6RDVEeEU2TVlHMUh2QTBpYlBFYUwwOENfN2pKTFl2eHhxYndqQ2tkeEdFZ1pGMkt5aU9qRElqb2dwRWpFY1NvSEhVM1o3a1ZWZXc3eHFzMG9RWnd3MW9mNU1nZHRyRmQxNVdSRERjQ1NM?oc=5","date":"2026-01-22","type":"pipeline","source":"RTTNews","summary":"Amylyx Pharma Hits New High - Delivers Over 160% Gain In 7 Months - RTTNews","headline":"Amylyx Pharma Hits New High - Delivers Over 160% Gain In 7 Months","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNblMtWUJ6bGxDS01FVzJNS2E3QVNpenY2aUZfeGNCZFROZTY4cC1xLVdWZ0pYa3RONTZYM1lZU01BZTRTWkZFeHVKbjl2a3lCdEwtWlBHRVZKRXNVaDE5Qmt4TXA1Y2lSR2p2NjNsUjdhYWtIT0tDVC1zd1NmeVo3blFtdWw2dldGcWx2cDBNTWJtYXFvQzNFVzFrNjdQTk40Z0lVQVVOcnBPeFFXWnpWYUtXb3lMQ3hVUmlSTUdn?oc=5","date":"2026-01-20","type":"pipeline","source":"Investing.com","summary":"Amylyx pharma co-CEO Klee sells $1.88 million in AMLX stock - Investing.com","headline":"Amylyx pharma co-CEO Klee sells $1.88 million in AMLX stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPeDFWQV9jS3FvRUFLODlmZ0YyZ0F2dl9waGpRZXhSY1dEOUJucVBVM1VZT2gtVEczamNJV1Bad2pSRzdBMHFlRXpWVzJGcHNZaXlta1pfNUhUcXcwZV83UGVUQzREc21fa255WmczWVpiNVlMYjlaMUYxSFdoZnFVQUQtWkk4cC1rQXZuTy1CbmpiTDNSamZFVDlwaU1iMnNjeDhSeU1JaGUzOFB1dEs1VQ?oc=5","date":"2026-01-20","type":"pipeline","source":"Investing.com","summary":"Amylyx pharma co-CEO Cohen sells $1.87m in shares - Investing.com","headline":"Amylyx pharma co-CEO Cohen sells $1.87m in shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxObVlYcGRzclNMd1luclR0OWFhUFNnNmlpUUFZbHdFajZZUGNUaU54Z0Z0Tl94ZGdXejB1bkJpSGF0NnJCcmdHc25DelQ3ejdjRkNLcXEtUC1aLXNZNzlLWjFxNXdqcEhOcENQUkZRZ3pNMmNTT0plZDYzbkVZUHhLemZJRUxIS09ZbDlXQkNfcExoem5pYlE?oc=5","date":"2025-12-12","type":"pipeline","source":"Pharma Voice","summary":"Amylyx pins its next hopes on a niche drug in the obesity space - Pharma Voice","headline":"Amylyx pins its next hopes on a niche drug in the obesity space","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxNNjNwcF92bkg3bHU2c0o5QUVwRl9iMFExTjczbW9jX3h3cDhranZuelgzLTM0OWNhcFV4OWQzblJhenhDN2NZdW9aUldqQlNzYjY4allHRXRVRjNFU0x5bUJQS3FkVmw3N2c3XzVJVWRsX2tueXRmNVU1U01RVEtjRUFmZ3pvRmdQanAzOC0yd05QSlNUT3lIclBpMlprUjNDZDFuaHpEV0ZpSURyTmc5MmJfd1VmN0dQdnlBd1ZnNWJLQmdrcmFMcUMwMk1FWjVxN2hCZHgxTGotWUFRTWc?oc=5","date":"2025-10-30","type":"earnings","source":"Business Wire","summary":"Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 - Business Wire","headline":"Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxOZTEtUThyVGxjYUhacElwX0FsaU1NUEhrR2E5c1NHQWhoNW1TY0lMQlo1VDZ1cXJFSEdfMWV4SEl3bDgwc2c2T01WUFRIUU5JYkNlRUZPbGtuS3pKRVNmc2w2MVpHeENTNHp2NC1sT21hY013NjBGUlVmaWhLSlRQMmJxdUxLSVIwVUtMYWtiMGhyeXlWQ1pNUmZPS3ZLbEp0Z1ljY1VUTXcxZS01R1hNYW5qZG1DcmxjZ095YVVIZFpTRUVoS0dNXw?oc=5","date":"2025-09-18","type":"pipeline","source":"WilmerHale","summary":"WilmerHale Advises Underwriters in Public Offering of Amylyx Pharmaceuticals - WilmerHale","headline":"WilmerHale Advises Underwriters in Public Offering of Amylyx Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxNdTVrX0ZjNmVWaHRzLWZpR0pKNUw4ckxmZTFiRnNGXzlmUzBjLWNuZnJoLUlfTEM3dVh5bjJiNndsWmJOVXRHckNKSE5IWWFVaEd5SUFWN2hqNzBaU2FuM3A3bUxteXZBZ2puNUlsd092UlpfdXYxZ250VElRTnV1bnZ0eERuVmVBWldjRkFTOWExaEZBNTlJYmR2ekVtTVUwbkthaElsWUxranpOa3k5aFBqSE5ZdUU4MzFtU01OTDJIc1JHV0pxQ2NJa3JuQlY2YTZLXy1TRkxjc2J2aWZYN1ZMclRlZUd5N0J4cWd2a0tFQQ?oc=5","date":"2025-09-10","type":"pipeline","source":"Business Wire","summary":"Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock - Business Wire","headline":"Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxQV3p0WXY5ZXdmOG1nQ0hYMFQyVWs2SDhvWjZYNm1XOGRBLXNPdzEtWGo5WTJvSVVRVi1icS05U1hQcUhGRGxGQWxxdF9qejJuWm1BYlRJT2dYaEVmTzkyclRQWllNSmVMSEZheW9TREtoQ05vTzUxQkdSSXE2UFFJOXNHSkNIU0RhU0szNVVTX1FIRU4zU1RLeWh6Q2d1LVZqRmIxNlJUZWFvSWplYWlWTjJoTW5DdnFYXy1Zc01QQzNiZmxSWVRjWU1ZQnFieE1sbDFwZG9JVGhOOVhZelpWM0ZMMXluU2VrdDBEVDliV0RyRmhZblVDREpvVkRhWGdhZTROUWZFaVlhM3FOWWJuRDZXemRkd21Tc2RDOEsxR3BHcW1saEItV1ZvUkxDendudDZBZHFwUlNCRzc2NVBCYmdrMzc?oc=5","date":"2025-08-28","type":"trial","source":"GlobeNewswire","summary":"Antisense Oligonucleotide Therapeutics Clinical Trial - GlobeNewswire","headline":"Antisense Oligonucleotide Therapeutics Clinical Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQRVRSUlBvUDdDVmVIOTZ5R2pUZ3dYeEZCRTJDR0JEY0oxMGl0MlMxck1Rd1QxNllDT2Exdy1ONVZWZV9pS0lwa0RqYnE4ZWlpYkNOY2tHUWdFd0hRNklVclRZTlZxVVZfMG1CNUR4QjBrY01OcmtDR0p3dXJZdVhNcS16SmpmOHZHTk1lRFV0blFHaElqTHpCUW10Qk9Wd2FzUGR3aTVlQ1lPSDY3ZHd1elVudy1QU0VVTEJ5QzAtSlZyaUNfNFBOTW5nZ1Z3RTQ2djRxbTBUMA?oc=5","date":"2025-08-27","type":"trial","source":"Reuters","summary":"Amylyx to stop development of rare brain disorder drug after trial failure - Reuters","headline":"Amylyx to stop development of rare brain disorder drug after trial failure","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOM3hoemVFQ3F2Z3lxZmNheGVQaVlxWTBnQnFmbVRhX05GRkhQZC10THBMcTUxT1FwQnh3Y21TclFibnh4UE92dnhNTzRpYVRlTGVIQktya1ZlR0d1Ukd1RklOMWM2NkVPdVlSck9ORTRTbmpoMDNpN0QweTlBcWlrWndpLW5sREpqUlMwQndUaXhIODlmU0JsWjBPZw?oc=5","date":"2025-07-15","type":"trial","source":"Yahoo Finance","summary":"Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion - Yahoo Finance","headline":"Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOaE9GanBabllHbDNPWGRmVmV6a1NzWVhsb245WlpzYkpTaWxkSUdJcFZybTQ3THVOTUtzZWJDZlp5UjYyNmFCMUVFR2NCR3lqRW00Y2pEZFJ6XzVfLWtRRHZ1VS1raE1nR2g2UFlXSnJIWW4ya0ZGeUlSdkpXbUhHd3k1MURZeHN6RE9CWWMwWXdmdGY5akkzNUhaOA?oc=5","date":"2024-04-04","type":"pipeline","source":"Fierce Pharma","summary":"Amylyx to pull failed ALS drug Relyvrio from market, cut 70% of staffers - Fierce Pharma","headline":"Amylyx to pull failed ALS drug Relyvrio from market, cut 70% of staffers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPOE9FRTVpMjVOYmJlUDdaLVBveEdWVC00LXpCOVRXamRRVW9Udm82bGN2WHl1ZTRTNHFlME9BQ1dqbjFLOXE2RmN6YkdFc2tHa0pOcW9CUWJVMXB2Y3JyX1hGTnRyRGEwTmtVbWhaMGJMR2JvM2h6d2hBb0JRTnNYdUt2UzdDMnlSUjlvRktEc3FwaFE?oc=5","date":"2021-03-29","type":"pipeline","source":"Amylyx","summary":"Paul Fonteyne Joins Amylyx Pharmaceuticals Board of Directors - Amylyx","headline":"Paul Fonteyne Joins Amylyx Pharmaceuticals Board of Directors","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_3":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":380786000,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":380786000,"period":"2023-12-31"},{"value":22230000,"period":"2022-12-31"},{"value":285000,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":90404000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-144735000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":226651000,"cashHistory":[],"totalAssets":332645000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}